vs
AC Immune SA（ACIU）与渤健（BIIB）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是AC Immune SA的1586.7倍（$2.3B vs $1.4M）。渤健净利率更高（-2.1% vs -1622.4%，领先1620.3%）。AC Immune SA同比增速更快（90.1% vs -7.1%）
AC Immune SA是一家临床阶段生物制药企业，专注于开发阿尔茨海默病、帕金森病及罕见tau蛋白病等神经退行性疾病的创新疗法与诊断方案，与全球领先药企展开合作，致力于满足神经疾病领域未被满足的临床需求。
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
ACIU vs BIIB — 直观对比
营收规模更大
BIIB
是对方的1586.7倍
$1.4M
营收增速更快
ACIU
高出97.2%
-7.1%
净利率更高
BIIB
高出1620.3%
-1622.4%
损益表 — Q2 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4M | $2.3B |
| 净利润 | $-23.3M | $-48.9M |
| 毛利率 | — | 78.3% |
| 营业利润率 | -1484.5% | -2.5% |
| 净利率 | -1622.4% | -2.1% |
| 营收同比 | 90.1% | -7.1% |
| 净利润同比 | 6.9% | -118.3% |
| 每股收益（稀释后） | — | $-0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACIUBIIB
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | $1.4M | $2.6B | ||
| Q1 25 | — | $2.4B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | $755.7K | $2.5B | ||
| Q1 24 | — | $2.3B |
净利润ACIUBIIB
| Q4 25 | — | $-48.9M | ||
| Q3 25 | — | $466.5M | ||
| Q2 25 | $-23.3M | $634.8M | ||
| Q1 25 | — | $240.5M | ||
| Q4 24 | — | $266.7M | ||
| Q3 24 | — | $388.5M | ||
| Q2 24 | $-25.0M | $583.6M | ||
| Q1 24 | — | $393.4M |
毛利率ACIUBIIB
| Q4 25 | — | 78.3% | ||
| Q3 25 | — | 73.4% | ||
| Q2 25 | — | 77.1% | ||
| Q1 25 | — | 74.1% | ||
| Q4 24 | — | 76.2% | ||
| Q3 24 | — | 74.1% | ||
| Q2 24 | — | 77.8% | ||
| Q1 24 | — | 76.3% |
营业利润率ACIUBIIB
| Q4 25 | — | -2.5% | ||
| Q3 25 | — | 22.0% | ||
| Q2 25 | -1484.5% | 28.1% | ||
| Q1 25 | — | 12.8% | ||
| Q4 24 | — | 11.9% | ||
| Q3 24 | — | 18.3% | ||
| Q2 24 | -3051.1% | 28.3% | ||
| Q1 24 | — | 20.3% |
净利率ACIUBIIB
| Q4 25 | — | -2.1% | ||
| Q3 25 | — | 18.4% | ||
| Q2 25 | -1622.4% | 24.0% | ||
| Q1 25 | — | 9.9% | ||
| Q4 24 | — | 10.9% | ||
| Q3 24 | — | 15.8% | ||
| Q2 24 | -3313.0% | 23.7% | ||
| Q1 24 | — | 17.2% |
每股收益（稀释后）ACIUBIIB
| Q4 25 | — | $-0.35 | ||
| Q3 25 | — | $3.17 | ||
| Q2 25 | — | $4.33 | ||
| Q1 25 | — | $1.64 | ||
| Q4 24 | — | $1.82 | ||
| Q3 24 | — | $2.66 | ||
| Q2 24 | — | $4.00 | ||
| Q1 24 | — | $2.70 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $28.3M | — |
| 总债务越低越好 | — | $6.3B |
| 股东权益账面价值 | $82.2M | $18.3B |
| 总资产 | $209.2M | $29.4B |
| 负债/权益比越低杠杆越低 | — | 0.34× |
8季度趋势，按日历期对齐
现金及短期投资ACIUBIIB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $28.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $56.7M | — | ||
| Q1 24 | — | — |
总债务ACIUBIIB
| Q4 25 | — | $6.3B | ||
| Q3 25 | — | $6.3B | ||
| Q2 25 | — | $6.3B | ||
| Q1 25 | — | $4.5B | ||
| Q4 24 | — | $6.3B | ||
| Q3 24 | — | $4.5B | ||
| Q2 24 | — | $6.3B | ||
| Q1 24 | — | $6.3B |
股东权益ACIUBIIB
| Q4 25 | — | $18.3B | ||
| Q3 25 | — | $18.2B | ||
| Q2 25 | $82.2M | $17.6B | ||
| Q1 25 | — | $17.0B | ||
| Q4 24 | — | $16.7B | ||
| Q3 24 | — | $16.4B | ||
| Q2 24 | $135.8M | $15.9B | ||
| Q1 24 | — | $15.2B |
总资产ACIUBIIB
| Q4 25 | — | $29.4B | ||
| Q3 25 | — | $29.2B | ||
| Q2 25 | $209.2M | $28.3B | ||
| Q1 25 | — | $28.0B | ||
| Q4 24 | — | $28.0B | ||
| Q3 24 | — | $28.3B | ||
| Q2 24 | $261.3M | $26.8B | ||
| Q1 24 | — | $26.6B |
负债/权益比ACIUBIIB
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.36× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | — | 0.28× | ||
| Q2 24 | — | 0.40× | ||
| Q1 24 | — | 0.41× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $511.9M |
| 自由现金流经营现金流 - 资本支出 | — | $468.0M |
| 自由现金流率自由现金流/营收 | — | 20.5% |
| 资本支出强度资本支出/营收 | — | 1.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $2.1B |
8季度趋势，按日历期对齐
经营现金流ACIUBIIB
| Q4 25 | — | $511.9M | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $160.9M | ||
| Q1 25 | — | $259.3M | ||
| Q4 24 | — | $760.9M | ||
| Q3 24 | — | $935.6M | ||
| Q2 24 | — | $625.8M | ||
| Q1 24 | — | $553.2M |
自由现金流ACIUBIIB
| Q4 25 | — | $468.0M | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $134.3M | ||
| Q1 25 | — | $222.2M | ||
| Q4 24 | — | $721.6M | ||
| Q3 24 | — | $900.6M | ||
| Q2 24 | — | $592.3M | ||
| Q1 24 | — | $507.3M |
自由现金流率ACIUBIIB
| Q4 25 | — | 20.5% | ||
| Q3 25 | — | 48.4% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | — | 29.4% | ||
| Q3 24 | — | 36.5% | ||
| Q2 24 | — | 24.0% | ||
| Q1 24 | — | 22.1% |
资本支出强度ACIUBIIB
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 2.0% |
现金转化率ACIUBIIB
| Q4 25 | — | — | ||
| Q3 25 | — | 2.73× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 1.08× | ||
| Q4 24 | — | 2.85× | ||
| Q3 24 | — | 2.41× | ||
| Q2 24 | — | 1.07× | ||
| Q1 24 | — | 1.41× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACIU
暂无分部数据
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
